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OBJECTIVES: To assess the prevalence and interrelationship between lower urinary tract symptoms and sexual
dysfunction in men with multiple sclerosis (MS).
METHODS: In a cross-sectional study, we evaluated 41 men (mean age 41.1±9.9 years) with MS from February
2011 to March 2013, who were invited to participate irrespective of the presence of lower urinary tract
symptoms or sexual dysfunction. Neurological impairment was assessed with the Expanded Disability Status
Scale; lower urinary tract symptoms were evaluated with the International Continence Society male short-form
questionnaire, and sexual dysfunction was evaluated with the International Index of Erectile Function. All
patients underwent transabdominal urinary tract sonography and urine culture.
RESULTS: The mean disease duration was 10.5±7.3 years. Neurological evaluation showed a median Expanded
Disability Status Scale score of 3 [2-6]. The median International Continence Society male short-form quest-
ionnaire score was 17 [10-25]. The median International Index of Erectile Function score was 29 [15-46]. Twenty-
nine patients (74.4%) had sexual dysfunction as defined by an International Index of Erectile Function score
o45. Voiding dysfunction and sexual dysfunction increased with the degree of neurological impairment (r=0.02
[0.02 to 0.36] p=0.03 and r=-0.41 [-0.65 to -0.11] p=0.008, respectively). Lower urinary tract symptoms and sexual
dysfunction also displayed a significant correlation (r=-0.31 [-0.56 to -0.01] p=0.04).
CONCLUSIONS: Most male patients with MS have lower urinary tract symptoms and sexual dysfunction. The
severity of the neurological disease is a predictive factor for the occurrence of voiding and sexual dysfunctions.
KEYWORDS: Bladder Dysfunction; Demyelinating Diseases; Erectile Dysfunction; Lower Urinary Tract Symptoms;
Multiple Sclerosis; Sexual Symptoms.
’ INTRODUCTION
Multiple sclerosis (MS) is the most common neurologi-
cal disease in young adults, with peak incidence between
ages 30 and 35 (1). It is a chronic and progressive immune-
mediated inflammatory disease that affects the central nervous
system. MS may manifest different neurological symptoms
and usually progresses to loss of physical and cognitive capa-
bilities (2,3).
Lower urinary tract symptoms (LUTS) are frequent in MS
patients (4). After 10 years of disease activity, it is estimated
that more than 90% of MS patients report LUTS, and 70-80%
have changes in voiding patterns during follow-up (4). Further-
more, LUTS are observed as the first manifestation of MS in 2 to
10% of patients (5). The impact of LUTS is significant, with
impairment of quality of life (QOL), social functioning and
sexual health (6,7). It is essential to understand the extent
of the problem and to provide effective treatment for the
affected individuals.
Sexual dysfunction (SD) is also highly prevalent in patients
with MS and is often overlooked (8,9). SD may have a tre-
mendous negative impact on the QOL, especially considering
that many patients are young individuals (8-10). It is esti-
mated that 50-90% of men with MS have SD, including erectile
dysfunction (ED), ejaculatory disorders, orgasmic dysfunction
and decreased libido (8,9).
An association seems to exist between LUTS and SD in
patients with neurological impairment (8,11). This associa-
tion is likely due to the common autonomic innervation of
the genitourinary tract (12). Even though the prevalence and
impact of LUTS and SD have been described in the MS popu-
lation, the association between these distinct entities and the
neurological status have not been properly investigated. More-
over, most studies have focused on female patients, who are
more commonly affected by the disease. We performed a cross-
sectional study to determine the prevalence and burden of LUTS
and SD in men withMS. In addition, we investigated their inter-
relationships and associations with neurological disability.DOI: 10.6061/clinics/2019/e713
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’ MATERIALS AND METHODS
Study Population
In a cross-sectional study conducted from February 2011 to
March 2013, we recruited consecutive male MS patients who
presented at our Neurology Clinic. Participants were adults
aged X21 years with a clinical diagnosis of MS according to
the McDonald criteria (13). To be included in the present
study, all subjects had to be in remission for at least 6 months
since the last exacerbation episode. The exclusion criteria
were prostate volume X30 g (as measured by transabdom-
inal sonography), urinary retention requiring an indwelling
catheter, previous history of pelvic or prostate surgery, pre-
vious pelvic radiotherapy, presence of bladder stones,
urethral stricture, pharmacological treatment with 5-alpha
reductase inhibitors or phosphodiesterase type 5 inhibitors
(PDE5), severe cognitive or neuromuscular impairment and
signs of disease exacerbation.
Neurological Assessment
The severity of neurological impairment was assessed with
the Expanded Disability Status Scale (EDSS, ranging from 0 to
10), which was performed by neurologists who specialized in
demyelinating diseases. EDSS scores are based on measures of
impairment in eight functional systems: visual, pyramidal,
sensory, cerebellar, bowel and bladder, cerebral, brainstem
and ambulation. EDSS steps 5.0 to 9.5 are characterized by
impaired walking. An EDSS score 48 refers to a bedridden
patient, which indicates severe cognitive and/or neuromus-
cular impairment; therefore, this value was used as a cutoff to
participate in the study. The duration of MS was defined as
the time since the first onset of neurological symptoms.
LUTS Assessment
LUTS were evaluated with the abbreviated questionnaire
of the International Continence Society for males (ICSmSF),
based on the ICS definitions of LUTS (14). This is a stan-
dardized instrument that collects information on hesitancy,
straining to void, slow stream, intermittency, incomplete
emptying, terminal dribble, urgency, urge incontinence,
stress incontinence, unpredictable urinary incontinence, noc-
turnal enuresis, frequency and nocturia. It provides not only
a total ICSmSF score but also scores for specific LUTS cate-
gories: voiding (ICSV), incontinence/storage (ICSI), and LUTS-
related QOL subscores (14). The answers are displayed as a
five-point Likert scale including ‘‘never’’ (0), ‘‘occasionally’’
(1), ‘‘sometimes’’ (2), ‘‘most of the time’’ (3) and ‘‘all of the
time’’ (4). Each LUTS was considered present whenever
‘‘sometimes’’, ‘‘most of the time’’ or ‘‘always’’ was indicated
(15). Increased urinary frequency was defined as intervals
p2 hours (14). Nocturia was defined as two or more voids
per night (16). QOL was scored from 0 to 3 according to
the degree of burden associated with LUTS: 0 (not at all),
1 (mild), 2 (moderate) and 3 (severe).
The workup also included serum creatinine and prostate
specific antigen (PSA) levels, urine culture and transabdom-
inal sonography for evaluation of the kidneys, bladder,
prostate and postvoid residual urine (PVR). Patients with a
positive culture were treated prior to completing the ICSmSF
questionnaire.
Sexual Function Assessment
Sexual function was evaluated using the International
Index of Erectile Function (IIEF-15) (17), which contains
15 questions evaluating five domains of sexual function:
erectile function (EF), orgasmic function, sexual desire,
satisfaction with sexual intercourse and overall satisfaction,
with total scores ranging from 5 to 75. Dysfunctions in each
domain were classified according to specific scoring as no
dysfunction, mild, mild to moderate, moderate, and severe
dysfunction (17). Severe impairment is associated with the
lowest scores. Patients with total IIEF scores p45 were
considered as having SD (17). EF was assessed by the IIEF-5
questionnaire, which is derived from the IIEF-15. Indivi-
duals with an IIEF score X17 were considered no to have
significant ED (18,19).
Associations among Neurological Impairment, LUTS
and SD
To investigate the association between neurological impair-
ment and LUTS, patients were stratified according to their
neurological disability based on the EDSS score. Patients were
also compared in terms of the total ICSmSF score and the
incontinence/storage subscore (ICSI). The EDSS scores were
correlated with the IIEF-15 scores to evaluate the influence of
the degree of neurological impairment on sexual function.
Finally, we investigated the direct association between LUTS
and SD by correlating ICSmSF and IIEF-15 scores.
Statistical Analysis and Ethical Considerations
Continuous or ordinal quantitative variables are described
by measures of central tendency (mean or median) and the
respective measures of dispersion (standard deviation or inter-
quartile range). Qualitative or categorical variables are des-
cribed using their absolute values or proportions. Student’s
t test, the Mann-Whitney test, the chi-squared test or Fisher’s
test were used as appropriate. The Pearson correlation test
was used to evaluate correlations between continuous vari-
ables. Statistical significance was defined as po0.05. Data
were processed using commercially available statistical soft-
ware (Graph Pad Prism version 5.0.3, Graph Pad Software,
San Diego, CA). This study was approved by the Institutional
Review Board of our hospital.
’ RESULTS
Study Population
A total of 41 men with an average age of 40.7±10.1 years
(ranging from 22 to 66 years) were evaluated. Thirty-five
(85.4%) patients were Caucasian, and 6 (14.6%) were African-
Brazilians. The mean disease duration was 10.5±7.3 (5-35)
years. The median EDSS score was 3.0 [range of 1.5 to 6].
Among the patients, 25 (61%) had scores between 1.0 and 4.5,
and 16 (39%) had scores X5.0. Demographic characteristics
are shown in Table 1.
Prevalence of LUTS
The overall prevalence of LUTS was 97.6%, with only one
patient presenting no symptoms. The most common storage
symptoms were urgency (70.7%), increased daytime fre-
quency (46.3%), urge urinary incontinence (36.6%), nocturia
(31.7%), unpredictable urinary incontinence (21.9%), noctur-
nal enuresis (19.5%), and stress urinary incontinence (9.8%).
Hesitancy was the most common voiding symptom (70.7%),
followed by intermittency (46.3%), feeling of incomplete
emptying (43.4%), weak stream (41.4%) and straining to
void (36.6%).
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Regarding the impact of LUTS on QOL, 11 (26.8%) patients
reported no bother, 22 (53.7%) reported mild to moderate
burden, and 8 (19.5%) reported severe burden. The preva-
lence of LUTS and the impact on QOL are shown in Table 2.
A significant association between the severity of LUTS and
the impact of LUTS on QOL was found. The highest cor-
relation coefficient was observed with symptoms of incon-
tinence (Figure 1). Table 3 compares the prevalence of LUTS
in our study of patients with MS compared to the general
population reported in the EpiLUTS study (15).
Urinary tract sonography was normal in 37 (90.2%) patients,
while four (9.8%) patients had kidney cysts. Prostate trans-
abdominal sonography demonstrated a PVR 4100 ml in 7
(17.1%) patients. The mean serum creatinine level was 0.77±
0.17 mg/dl (range 0.63–1.2), and the mean serum PSA level
was 0.64±0.11 ng/ml (range 0.1-1.98). Urine culture was
positive in 8 (19.5%) patients.
Prevalence of SD
A total of 39 (95.1%) men reported being sexually active.
Their median IIEF-15 score was 29 [15-46]. A total of 29
(74.4%) had SD (IIEF-15p45). Significant ED (IIEF-5p16)
was reported by 26 (66.7%) patients, including severe ED in
17 (43.6%) and moderate ED in 9 patients (23.1%). Orgasmic
dysfunction was graded as severe in 14 (35.9%) patients,
moderate in 5 (12.8%) patients, mild to moderate in 5 (12.8%)
patients and mild in 7 (18%) patients; 8 (20.5%) patients
reported normal orgasmic function. The decrease in sexual
desire was classified as severe in 2 (5.1%) patients, moderate
in 11 (28.2%) patients, mild to moderate in 4 (10.3%) patients
and mild in 10 (25.6%) patients; 12 (30.8%) patients repor-
ted normal sexual desire. Twenty-three (59%) patients
reported moderate or severe dissatisfaction with sexual
intercourse (23.1% and 35.9%, respectively), and 3 (7.7%)
considered themselves satisfied. Regarding the overall
satisfaction with sexual life, 11 (28.2%) patients considered
themselves as severely dissatisfied, 10 (25.6%) considered
themselves moderately dissatisfied, 9 (23.1%) considered them-
selves mildly to moderately dissatisfied, and 3 (7.7%) con-
sidered themselves mildly dissatisfied; 6 (15.4%) patients were
satisfied. Table 4 summarizes the prevalence of SD accord-
ing to IIEF domains.
Associations among Neurological Impairment and
LUTS and SD
Patients with more severe neurological impairment (EDSS
X4.5) had worse storage symptoms according to the ICSI
score (6 [4-10] vs. 4 [2-6]; p=0.014), while the total ICSmSF
score did not differ significantly (17 [11-23] vs 13 [8-21];
p=0.267). A significant correlation was found between the
EDSS score and the IIEF-15 score (r=-0.41 [-0.65 to -0.11];
p=0.008), demonstrating that higher degrees of neurological
deficit are associated with a higher prevalence of SD. The
association between the EDSS and IIEF-15 scores is displayed
in Figure 1. A correlation was observed between the severity
of LUTS and the presence of SD (r=-0.31 [-0.56 to -0.01];
p=0.04), demonstrating that more severe LUTS are associated
with worse sexual function.
’ DISCUSSION
In this cross-sectional study, we evaluated a population of
men with MS to determine the prevalence and characteristics
of LUTS and SD and their relationship to neurological
impairment. LUTS were present in all but one man in our
patient population (97.6%), based on the definition used in
most population-based studies: symptoms occurring some-
times, most of the time or all of the time. Storage symptoms
were reported by 85% of the patients and represented the
most common ICS category of symptoms, with urgency
(70.7%), frequency (46.3%) and urge urinary incontinence
(36.6%) as the most common symptoms. Voiding symptoms
were present in 72.5% of the patients, with hesitancy (70.7%),
intermittency (46.3%) and feeling of incomplete emptying
(43.4%) as the most prevalent symptoms. Symptoms were
commonly bothersome: 53.7% of patients were mildly to
moderately burdened and 19.5% of patients were severely
burdened by LUTS. As expected, symptom severity was
associated with symptom burden.
Studies have shown that most patients with MS will
develop LUTS during the course of the disease (20,21).
According to a database of the North American Research
Committee on Multiple Sclerosis with more than 9700
patients, 65% report moderate to severe LUTS (22). Storage
symptoms are the most frequent in patients with MS (23).
Urgency, frequency and urge incontinence can be present
in 19 to 85% of patients (24,25). The reported prevalence
Table 1 - Demographic and clinical data of male patients
with MS.
Age 40.7±10.1 (range 22-66) years
Race
Caucasian 35 (85.4%)
African-Brazilian 6 (14.6%)
Other 0
Marital status
Married/living with partner 21 (48.8%)
Single 14 (34.2%)
Divorced 6 (14.6%)
Widower 0
MS duration 10.5±7.3 (range 5-35) years
EDSS median 3.0 (1.5-6)
Table 2 - LUTS in men with MS.
LUTS - Storage symptoms n (%)
Urgency 29 (70.7%)
Increased daytime frequency 19 (46.3%)
Urge urinary incontinence 15 (36.6%)
Nocturia 13 (31.7%)
Continuous urinary incontinence 9 (21.9%)
Nocturnal enuresis 8 (19.5%)
Stress urinary incontinence 4 (9.8%)
LUTS - Voiding symptoms
Hesitancy 29 (70.7%)
Intermittent stream 19 (46.3%)
Slow stream 17 (41.4%)
Straining 15 (36.6%)
LUTS - Postmicturition
Incomplete emptying 18 (43.4)
ICSmSF median 15 (9-22)
ICSI 5.6±0.8
ICSV 6.8±0.4
ICSF 1.4±0.7
Nocturia 1.0±0.7
Quality of life (QOL)
Not bothered 11 (26.8%)
Mildly bothered 18 (43.9%)
Moderately bothered 4 (9.8%)
Severely bothered 8 (19.5%)
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of voiding symptoms in MS patients is 37-72% (5,26-29).
The overall prevalence of LUTS in our sample of men with
MS (97.6%) was comparable to that in other series (52-97%)
(5,26), and storage symptoms were the most common LUTS.
We also found a high prevalence of voiding symptoms, which
have been shown to be more common in men (5,29).
Considering differences in study populations and methods
of evaluating LUTS, our findings appear consistent with other
studies. Our observation that LUTS affects the QOL of most
MS patients is consistent with other studies that have shown
that LUTS are among the most uncomfortable and limiting
symptoms that affect these patients, as they deteriorate
their work and social activities, self-esteem and psycholo-
gical status (12,26).
Most subjects (95.1%) in our study were sexually active.
Their sexual function, however, was markedly affected in
many domains, with 3 of every four patients classified as
having SD (IIEF-15p45). ED (IIEF-5p16) was reported by
two-thirds of the patients, with severe ED in 43.6%. Moderate
or severe orgasmic dysfunction was present in 48.7% of the
patients, with only 20.5% reporting normal orgasmic function.
Decreased sexual desire was also common and was moderate
or severe in 33.3% of patients, while only 30.8% reported
normal sexual desire. Most patients (59%) reported moderate
or severe dissatisfaction with sexual intercourse, and only
7.7% considered themselves satisfied. In terms of satisfaction
with sexual life, 53.8% of subjects considered themselves
as moderately or severely dissatisfied, and only 15.4% were
satisfied.
As with LUTS, SD also has a tremendous negative impact
on the QOL of people with MS (8). Our findings for SD are
consistent with most studies, which have demonstrated that
50-90% of men with MS have SD (26). ED is reported as the
most common problem, followed by ejaculatory and/or
orgasmic dysfunction and reduced libido (9). We observed
significant impairment of EF, orgasm and sexual desire.
Accordingly, patients reported low rates of satisfaction with
sexual life.
LUTS and SD have been shown to be correlated in
individuals with or without neurological diseases (11,18),
reinforcing the concept of a common etiology for both dys-
functions. MS results in a demyelination process that inter-
rupts the continuity of the neural pathways, which has the
potential to substantially alter the neurophysiology of both
the lower urinary tract function and sexual function. Our
findings corroborate the association between LUTS and SD
Figure 1 - (a) Association between neurological impairment (EDSS) and lower urinary tract symptoms (ICSmSF) (r=0.16 [0.02 to 0.36]
p=0.29). (b) Association between neurological impairment (EDSS) and sexual function (IIEF-15) (r=-0.41 [-0.65 to -0.11]; p=0.008).
(c) Association between lower urinary tract symptoms (ICSmSF) and sexual function (IIEF-15) (r=-0.31 [-0.56 to -0.01]; p=0.04).
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in MS, based on the significant correlation between the
ICSmSF and the IIEF-15 scores. Voiding dysfunction has
been shown to be independently associated with SD after
adjustment for psychological factors in a multivariable
model (30). Francomano et al. (31) investigated the impact
of daily tadalafil treatment on LUTS and SD in men with MS
and demonstrated significant improvements in storage
symptoms, PVR volume and EF. In an Italian study with
101 male patients, Balsamo et al. demonstrated that depres-
sion and urinary symptoms measured by the International
Prostate Symptom Score (IPSS) were the only independent
predictors of ED in this study population (32). Finally,
urodynamic abnormalities such as detrusor overactivity and
low bladder capacity have been shown to correlate with SD
in both men and women.
The severity of LUTS has been shown to correlate with the
degree of neurological impairment in MS patients (5,12) and
other neurological diseases such as Parkinson’s Disease (33)
and neuromyelitis optica (34). Zecca et al. evaluated 403 men
and women with MS and found that urinary incontinence
has a strong positive correlation with EDSS scores in both
genders (4). Araki et al. showed that storage but not voiding
symptoms correlated with EDSS scores (35). Our findings
were consistent with these results, confirming the association
between neurological impairment and storage symptoms
measured by the ICSI score.
SD appears to be highly correlated with the severity of
neurological impairment, affecting approximately 80% of
patients with an EDSS score 44.0 (10). Our results confirm
this association, showing a significant correlation between the
EDSS and the IIEF-15 scores. The pathophysiology of SD in
patients with MS is multifactorial, involving physical, psy-
chological and social factors (36). Marck et al. (36) demon-
strated that SD and low satisfaction with sexual life are
associated with depression and fatigue, as well as with modi-
fiable lifestyle factors such as diet and physical activity.
Fragala et al. (18) found that, in addition to neurological dis-
ability, depression and the presence of detrusor overactivity
were independent predictors of SD in men and women.
The strengths of this study include the evaluation of
both LUTS and SD in men using well-established, validated
diagnostic tools with definitions of symptoms based on the
ICS definitions of LUTS. Moreover, questionnaires were com-
pleted in the setting of a medical evaluation and not based on
only self-reported responses or on telephone interviews
during which subjects may not always provide accurate
answers. The relatively small sample size is a limitation of
Table 3 - Prevalence of LUTS in men with MS found in the present study in comparison to the general population reported in the
EpiLUTS study.
Condition, n (%) Men with MS (present series) Men in the general population
(EpiLUTS study)
LUTS at least
‘‘sometimes’’
LUTS at least
‘‘most often’’
LUTS at least
‘‘sometimes’’
LUTS at least
‘‘often’’
No. of participants 41 41 14,139 14,139
Voiding symptoms
Weak stream 15 (36.6) 9 (21.9) 3,803 (27.0) 1,356 (9.6)
Split stream - - 2,743 (19.5) 694 (4.9)
Intermittency 19 (46.3) 9 (21.9) 2,632 (18.7) 721 (5.1)
Hesitancy 29 (70.7) 9 (21.9) 2,833 (20.1) 751 (5.3)
Straining 15 (36.6) 5 (12.2) 1,092 (7.7) 275 (2.0)
Terminal dribble - - 6,410 (45.5) 2,755 (19.6)
Storage symptoms
Perceived frequency, yes 19 (46.3) - 2,895 (20.5) 2,895 (20.5)
Nocturia X1 27 (65.8) - 9,788 (69.4) -
Nocturia X2 13 (31.7) - 4,021 (28.5) -
Nocturia X3 - - - 1,825 (12.9)
Urgency 29 (70.7) 12 (29.3) 3,104 (22.4) 674 (4.9)
Urgency with fear of leaking - - 1,975 (14.0) 546 (3.9)
Urgency incontinence 15 (36.6) 1 (2.4) 1,315 (9.3) 639 (4.5)
Stress incontinence
Laughing, sneezing, coughing 4 (9.7) 2 (4.9) 163 (1.2) 63 (0.4)
Physical activities - - 183 (1.3) 85 (0.6)
Leak for no reason 9 (21.9) 2 (4.9) 196 (1.4) 124 (0.9)
Nocturnal enuresis 8 (19.5) 3 (7.3) 201 (1.4) 116 (0.8)
Leak during sexual activity - - 36 (0.3) 11 (0.1)
Postmicturition
Incomplete emptying 18 (43.9) 5 (12.2) 3,209 (22.7) 764 (5.4)
Postmicturition incontinence 18 (43.9) 3 (7.3) 4,202 (29.7) 2,333 (16.5)
Table 4 - Sexual Dysfunction in men with MS.
Sexual Function n=39
SD 29 (74.4%)
No SD 10 (25.6%)
IIEF-15 median 29 (15-46)
Erectile dysfunction 26 (66.7%)
Orgasmic dysfunction 19 (48.7%)
Decreased sexual desire 13 (33.3%)
Dissatisfaction with sexual intercourse 23 (59%)
Overall satisfaction with sexual life 21 (53.8%)
MS = multiple sclerosis; EDSS = Expanded Disability Status Scale; LUTS =
lower urinary tract symptoms; ICSmSF = International Continence Society
male short form; ICSI = International Continence Society male short form
storage symptoms (incontinence); ICSV = International Continence Society
male short form voiding symptoms; ICSF = International Continence
Society male short form frequency; QOL = quality of life; SD = sexual
dysfunction; IIEF-15 = International Index of Erectile Function-15.
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the study, but it must be noted that we included only men.
Another limitation of the study was that we did not control
for the possible effects of medications used for MS treatment
on LUTS or SD. Because patients were using several medi-
cations from different drug classes, our sample would be
underpowered to analyze their effects.
’ CONCLUSION
LUTS and SD are highly prevalent in men with MS, and
both have a negative impact on QOL. The severity of
neurological impairment correlates with the severity of LUTS
and SD. Given the high prevalence of LUTS and SD in men
with MS, a more attentive focus on these areas is essential to
help patients achieve better control of LUTS and improve their
sexual health with consequent benefits to their QOL.
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